Clinical trial
MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions
NCT02663323 is registered in ClinicalTrials.gov with Meril Life Sciences Pvt. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions
- Lead sponsor
- Meril Life Sciences Pvt. Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- February 2, 2016
- Completion date
- July 5, 2020
- Enrollment
- 64 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.